Drugs / Allogeneic umbilical cord mesenchymal stem cells
Allogeneic umbilical cord mesenchymal stem cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03186456 | Dec 2026 → Jun 2027 | cerebral infarction | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03184935 | Dec 2026 → Jun 2027 | myelodysplastic syndrome | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT03180450 | Dec 2025 → Jun 2026 | heart failure | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT05501418 | Aug 2020 → Dec 2025 | COVID-19 | Ever Supreme Bio Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic umbilical cord mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03184935 ↗ |
| Known as | hUC-MSC | “The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.” NCT03184935 ↗ |
| Known as | SCLnow 19# | “Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)” NCT03184935 ↗2“Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)” NCT03186456 ↗ “Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)” NCT03180450 ↗ |
| Modality | Cell therapy | “human umbilical cord mesenchymal stem cells (hUC-MSC)” NCT03180450 ↗ |
| Route | Intravenous | “Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.” NCT03180450 ↗ |